Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-5 of 5
Keywords: Entacapone
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (2017) 78 (3-4): 143–153.
Published Online: 16 August 2017
...Jia Li; Zhiwei Lou; Xiaoyang Liu; Yajuan Sun; Jiajun Chen Aims: To assess the efficacy and safety of adjuvant treatment with entacapone in the treatment of later Parkinson’s disease (PD) patients with motor fluctuation. Methods: We conducted a systematic review of relevant studies from 8 databases...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (2009) 61 (2): 69–75.
Published Online: 28 November 2008
... daily doses of levodopa/DDCI were randomized to either levodopa/DDCI and entacapone or an increased dose frequency of levodopa/DDCI with or without an increased total daily dose (dose fractionation). After 1 month of treatment, patients were followed up for 1 year. A greater proportion of levodopa/DDCI...
Journal Articles
Subject Area:
Neurology and Neuroscience
N.I. Triantafyllou, E. Kararizou, E. Angelopoulos, S. Tsounis, F. Boufidou, M.E. Evangelopoulos, C. Nikolaou, D. Vassilopoulos
Journal:
European Neurology
Eur Neurol (2007) 58 (2): 96–99.
Published Online: 12 June 2007
... results may be worthy of clinicians’ attention [ 11,12,13 ]. In these situations we suggest supplementary treatment with vitamin B12 and folate. B12 vitamin Catechol-O-methyltransferase Catechol-O-methyltransferase inhibitors Entacapone Folate Folic acid Levodopa Parkinson’s disease...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (2001) 46 (1): 11–16.
Published Online: 12 July 2001
... hypotension, 2 increments of liver enzymes) or because of mandatory indications of the European drugs authority. All patients, after 3–6 months of L -DOPA therapy adjustments, received entacapone for 3 months again followed by withdrawal. L -DOPA daily dosage was significantly reduced by tolcapone...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (2001) 45 (2): 111–118.
Published Online: 16 February 2001
...F. Durif; I. Devaux; J.-J. Pere; J.-C. Delumeau; I. Bourdeix Entacapone is a potent, reversible and orally active inhibitor of catechol- O -methyltransferase. This open multicenter study evaluated the efficacy, safety and tolerability of entacapone as adjunct therapy to levodopa/dopa decarboxylase...